SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JFitnich who wrote (198)5/24/2003 1:27:55 AM
From: Miljenko Zuanic   of 590
 
JF,

15% Response? One or two pts one way or another, and this 15% may change. I hope that they will report data on bit more than first 40 subject, let say 70-80 subject. Also, it is more important and telling data from time to response, time to relapse, survival, QOL, and other things (like Viagra prescriptions ...grrrr).

I am tickled (like many others) why company is reporting only data from monotherapy trials. I guess AMGN want to keep low profile in regards the IMCL patents.

I will also base my future ABGX decision on ASCO data.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News